Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EHang Holdings Ltd - ADR (EH) vs McKesson Corporation (MCK) Price & Performance

EHang Holdings Ltd - ADRTrade
McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

EHang Holdings Ltd - ADR vs McKesson Corporation — how do they compare? EHang Holdings Ltd - ADR trades at $5.46 (market cap $414.87M), while McKesson Corporation trades at $830.7 (market cap $93.23B). The key difference: McKesson Corporation is far larger — about 224.7× EHang Holdings Ltd - ADR's market cap, and McKesson Corporation pays a 0.41% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals.

EHMCK
Market Cap
$414.87M$93.23B
Sector
IndustrialsHealth
52-Week High
$19.99$995.69
52-Week Low
$5.41$659.01
Enterprise Value
$354.54M$97.87B
Dividend Yield
0.41%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EHang Holdings Ltd - ADR

EHang Holdings (EH) trades at $5.56, up 2.02% on the day, amid mixed technical and fundamental signals. The stock shows a bearish technical trend with oversold short-term RSI, while fundamentally, the company reported Q1 2026 revenue of $418M, flat year-over-year but sharply lower sequentially due to delivery timing. The company remains unprofitable with a net margin of -77.56% and negative ROE of -34.03%, though it maintains a strong cash position of $1.12B and recently announced a $30M share repurchase program.

The outlook is bifurcated between significant long-term potential in the advanced air mobility market and near-term execution and profitability challenges. Investment opportunity lies in the company's first-mover technology and global regulatory progress, but risks include persistent cash burn, high valuation multiples despite losses, and intense competition in the emerging eVTOL sector. Analyst consensus is divided with a $6.97 price target but equal buy/hold/sell ratings.

McKesson Corporation

McKesson (MCK) trades at $803.37, down 1.1% on the day, with technical indicators showing a neutral to bullish bias as the price sits near pivot point $805. The company demonstrates strong fundamental momentum with revenue growing from $264B in 2022 to $359.1B in 2025, and a consistent track record of beating earnings estimates in recent quarters. Analyst sentiment is overwhelmingly positive, with 80% recommending Buy and a consensus price target of $932.83, representing a 16% upside from current levels.

The outlook for MCK is favorable, supported by robust revenue growth, expanding profitability, and strong analyst conviction. Key opportunities include continued execution in specialty pharma and oncology services. Primary risks involve policy changes affecting healthcare distribution, intense industry competition, and execution challenges in integrating growth initiatives, which could pressure margins.

Returns comparison

Trailing returns across standard periods

About EHang Holdings Ltd - ADR

EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

Read more on EH

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK